ArticleBMC cancer2026
Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo investigate novel combination strategies for TP53-mutated acute myeloid leukemia (AML), focusing on the potential synergy between PI3Kγ inhibition and Azacitidine, and to elucidate the underlying molecular mechanisms. MATERIALS AND
methodsWe detected the expression of PI3Kγ (PIK3CG/PIK3R5) in TP53 mutant and wildtype AML cell lines using the CCLE database, RT-qPCR, and western blot. We evaluated the influence of Azacitidine (AZA) and PI3Kγ inhibitor (Eganelisib) in AML cells, conducted in vivo combination therapy experiments, and identified synergistic targets through RNA sequencing and siRNA technology.
resultsTP53-mutated AML showed hypermethylation of PI3Kγ promoters and reduced PI3Kγ expression. AZA treatment selectively activated the PI3Kγ signaling in TP53-mutated cells. Eganelisib combined with AZA demonstrated potent synergy, suppressing proliferation and inducing apoptosis in TP53-mutated AML (ZIP synergy score > 10). This combination extended survival in xenograft models (33.0 vs. 18.0 days, p < 0.01). RNA-seq identified serglycin (SRGN) as a candidate mediator potentially linking AZA-induced transcriptional reprogramming to ROS-mediated cell death. SRGN knockdown elevated ROS levels and sensitized cells to AZA. The combinatorial treatment significantly increased ROS levels compared to monotherapy.
conclusionWe provide the first preclinical evidence that PI3Kγ inhibition sensitizes TP53-mutated AML to AZA through a mechanism potentially involving the SRGN-ROS axis, offering a translatable combinatorial strategy for patients with this aggressive leukemia subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.